News

Type 2 diabetes lower in familial hypercholesterolemia

View on the News

Findings shouldn’t alter current statin use

The findings by Besseling et al. should allay any concerns physicians may have about using statins in patients who have familial hypercholesterolemia. The drugs are now known to promote type 2 diabetes in the general population, but these patients appear to be at low risk for that metabolic disorder.

The study results do not, and should not, alter the use of these important medications in patients at elevated cardiovascular risk, who clearly benefit from statin therapy.

Dr. David Preiss and Dr. Naveed Sattar are at the BHF Glasgow Cardiovascular Research Centre at the University of Glasgow. Dr. Preiss reported serving as a consultant for Sanofi-Aventis; Dr. Sattar reported financial relationships with Amgen, Kowa Pharmaceuticals, and Sanofi-Aventis. They made these remarks in an editorial accompanying Dr. Besseling’s report (JAMA 2015;313:1016-7).


 

FROM JAMA

References

The prevalence of type 2 diabetes appears to be significantly lower in patients with familial hypercholesterolemia than in their unaffected relatives, according to a report published online March 10 in JAMA.

In an observational cross-sectional analysis of data from a nationwide Dutch registry of familial hypercholesterolemia, the prevalence of type 2 diabetes was 1.75% in 25,137 patients with the disorder, compared with 2.93% in 38,183 of their unaffected relatives. If this finding is confirmed in further research, it would support the hypothesis that cellular cholesterol metabolism plays a role in the development of type 2 diabetes, “perhaps because increased intracellular cholesterol levels are detrimental for pancreatic beta-cell function,” said Dr. Joost Besseling of the department of vascular medicine, Academic Medical Centre, Amsterdam, and his associates.

Patients with familial hypercholesterolemia require strict clinical follow-up, and it has been noticed – but, until now, not substantiated – that they are less prone to developing type 2 diabetes.

In what they described as the first study to examine this relationship, Dr. Besseling and his colleagues found that the strong inverse association (odds ratio, 0.62; 95% confidence interval, 0.55-0.69) between familial hypercholesterolemia and type 2 diabetes was consistent across every subgroup they evaluated, regardless of patient age, statin use, smoking status, and other possible confounding factors.

In addition, they found that the severity of the genetic mutation underlying the familial hypercholesterolemia also correlated, in an inverse dose-response manner, with the prevalence of type 2 diabetes (JAMA 2015;313:1029-36).

If these findings are confirmed, “they might provide support for development of new approaches to the prevention and treatment of type 2 diabetes by improving function and survival of pancreatic beta cells,” the investigators said.

Recommended Reading

High-fiber diet a viable weight-loss alternative to AHA recommendations
MDedge Family Medicine
Look for adverse events in patients with chronic urticaria
MDedge Family Medicine
Emulsifiers alter gut bacteria in mice, set the stage for IBD and metabolic syndrome
MDedge Family Medicine
Poor response to statins predicts growth in plaque
MDedge Family Medicine
Headway being made in developing biomarkers for PTSD
MDedge Family Medicine
Smart diet remains potent cardiovascular medicine
MDedge Family Medicine
VIDEO: Metabolic syndrome less likely in kids who eat nuts
MDedge Family Medicine
Fitter veterans have 35% lower health care costs
MDedge Family Medicine
Microbiome research is decades away from benefiting human health
MDedge Family Medicine
More coronary artery calcification seen with sedentary behavior
MDedge Family Medicine